Home > Journals > Minerva Anestesiologica > Past Issues > Articles online first > Minerva Anestesiologica 2020 Feb 17

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

 

 

Minerva Anestesiologica 2020 Feb 17

DOI: 10.23736/S0375-9393.20.14169-5

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Presepsin as a biomarker in perioperative medicine

Jessica HANDKE 1, Ornella PIAZZA 2 , Jan LARMANN 1, Simonetta TESORO 3, Edoardo DE ROBERTIS 3

1 Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany; 2 Department of Medicine and Surgery, University of Salerno, Baronissi, Sassari, Italy; 3 Department of Surgical and Biomedical Sciences, University of Perugia, Perugia, Italy


PDF


Presepsin is the soluble fragment of CD14, a multifunctional glycoprotein expressed on the surface of innate immune cells. In healthy individuals, presepsin is present in very low concentrations with reference values ranging from 60 to 382 pg/ml. Several studies have shown that presepsin is a valuable biomarker for sepsis diagnosis in adults. Only lately, presepsin has been evaluated for prediction and early detection of neonatal sepsis and septic shock. Elevated plasma presepsin concentration has also been reported in patients undergoing cardiac and non- cardiac surgery and it has further been evaluated as a potential independent predictor of perioperative cardiovascular complications and mortality. Combined cardiac and inflammatory biomarker evaluation may offer additive predictive information, but further investigations in large populations are required to determine presepsin diagnostic and prognostic value, in order to personalise therapy and reduce surgical patients’ morbidity and mortality.


KEY WORDS: Presepsin; Sepsis; Perioperative risk evaluation; Biomarkers

top of page